Comparative Pharmacology
Head-to-head clinical analysis: SERZONE versus TRINTELLIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SERZONE versus TRINTELLIX.
SERZONE vs TRINTELLIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Serzone (nefazodone) is a serotonin antagonist and reuptake inhibitor (SARI). It blocks postsynaptic 5-HT2 receptors and inhibits serotonin and norepinephrine reuptake, leading to increased serotonergic and noradrenergic neurotransmission.
Trintellix (vortioxetine) is a serotonin modulator and reuptake inhibitor. Its exact mechanism is not fully understood, but it is thought to work by inhibiting the reuptake of serotonin (5-HT) and by modulating several serotonin receptors, including 5-HT1A agonism, 5-HT1B partial agonism, 5-HT3 and 5-HT7 antagonism.
Initial 100 mg orally twice daily; titrate to 200-300 mg twice daily. Maximum 600 mg/day.
10 mg orally once daily initially, then increase to 20 mg orally once daily based on tolerability; maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is 18-22 hours for nefazodone; steady-state achieved in 3-5 days.
Terminal elimination half-life is approximately 66 hours (range 58-78 hours) for vortioxetine. This supports once-daily dosing; steady-state is reached within 2-3 weeks.
Primarily hepatic metabolism; <1% excreted unchanged renally; metabolites excreted in urine (approximately 85%) and feces (approximately 15%).
Primarily hepatic metabolism via CYP3A4 and CYP2C19, with approximately 26% of the dose recovered in urine (mostly as metabolites) and 60% in feces (mostly as metabolites). Less than 1% excreted as unchanged drug in urine.
Category C
Category C
Antidepressant
Antidepressant